Monday, May 25, 2026 Sign In Register FREE My Account Help

Explore

Flamenet Tools

Make FlameNet your home page

Opinion Home

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic color – PR Newswire

Posted by admin on Monday, May 25, 2026 at 10:11 am — No Comments | Leave a Comment

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic color PR Newswire

« Pope Leo Warns of Risks From A.I. in 42,300-Word Encyclical – The New York Times5 On Your Side: Beware summer travel scams – WRAL »

COMMENTS (0)

Leave a Comment

Cancel reply

You must be logged in to post a comment.